Theravance Biopharma Acquired by Zymeworks for $17.00 per Share in Cash Deal

Theravance Biopharma (TBPH) announces a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, which equates to an estimated equity value of around $929 million. This acquisition is a result of a thorough strategic alternatives review orchestrated by Theravance's Board of Directors and its Strategic Review Committee. Following consultations with Lazard, the board has determined that this acquisition maximizes shareholder value, particularly considering its recent successful monetization of the TRELEGY® royalty interest valued at $225 million in 2025. Moreover, this offer represents a 22% premium over the stock’s closing price as of March 3, 2026, which is significant given the context of the preliminary results from the Phase 3 CYPRESS study involving ampreloxetine.

Strategic Value and Opportunities for Shareholders

The deal entails that Theravance shareholders will not only receive immediate cash but also a contingent value right (CVR) that allows them to retain 80% of the net proceeds from any future licensing or monetization of ampreloxetine over the next decade. This structure has received positive comments from Theravance's Board. Independent Chair Susannah Gray articulates that the agreement validates the worth of their current assets and presents immediate cash to shareholders, while simultaneously providing a pathway for potential future profits from ampreloxetine developments.

Rick E Winningham, CEO of Theravance, expresses pride in the company's accomplishments and acknowledges the dedicated efforts of the team to reach this important milestone. The acquisition is expected to be finalized in the second half of 2026, pending shareholder and regulatory approvals. As Theravance moves forward with this acquisition, it sets the stage for broader trajectories not only for the company but also for Zymeworks as it seeks to enhance its biopharmaceutical portfolio and market presence.

Ongoing Investigations into the Acquisition Deal

In the meantime, shareholder litigation firms including Ademi LLP and Monteverde & Associates PC have initiated investigations into the acquisition deal. The inquiries focus on potential fiduciary duty violations by Theravance’s Board of Directors and whether the terms proposed ensure fair compensation for shareholders. These investigations highlight the scrutiny faced by the deal and underline the critical importance of fidelity to shareholder interests during major corporate transactions.

Encouragement for Shareholder Vigilance

As the situation evolves, shareholders are encouraged to stay informed and consider their legal options regarding the transaction.